

ANNUAL REPORT 2021-22

0

PARTNERS



We wish to acknowledge the ongoing support we receive through the following Memorial Funds:

Anna Oszlanszki Memorial Fund

Colin Cyril Telfer Memorial Fund

Johanna Wyld Memorial Fund

Benny Therp-Olesen Memorial Fund

Thanks to Greater Good for managing these funds.

We would like to say a very special thank you to our volunteers. You are the heart of our organisation, and your generosity is deeply appreciated.

ACKNOWLEDGEMENT OF COUNTRY

Cancer Council ACT acknowledges the Ngunnawal people as the traditional custodians of the ACT and surrounding areas.

We pay our respects to Aboriginal and Torres Strait Islander cultures and to Elders past, present and emerging.



A MESSAGE FROM OUR PATRON, HER EXCELLENCY MRS LINDA HURLEY

It is a privilege for me to provide this message of support to Cancer Council ACT, an organisation that continues to make an enormous difference to the lives of people living with cancer and their families.

In May, David and I had the pleasure of hosting a Biggest Morning Tea at Government House and meeting some of Cancer Council ACT's wonderful volunteers and fundraisers. The event was made even more special as we announced the Cancer Council ACT Research Grant Recipients for 2022, Dr Mathur and Dr Ferreira. They are incredibly talented and amazing people and I look forward to hearing about the impact of their work on the treatment and prevention of cancer in the future.

One of the ways the funds raised from the Biggest Morning Tea help Cancer Council ACT is through the Wig Service. In June, David and I visited the Wig Studio in Deakin to meet with those involved in the service and hear first-hand about the wonderful work they do for the Canberra community.

I want to thank all involved with Cancer Council ACT for your tireless efforts in working to achieve a world without cancer. I look forward to continuing to support the work of Cancer Council ACT as Patron and being part of this welcoming and kind community.

Kind regards, Her Excellency, Mrs Linda Hurley

Professor Paul Craft (CCACT Board), Professor Si Ming Man, Her Excellency Mrs Linda Hurley, Dr Anukriti Mathur, His Excellency General the Honourable David Hurley AC DSC (Retd), Roger Buckley (CCACT Board President).



Cancer Council ACT Staff, Phil Greenwood (CCACT Board Vice-President), Roger Buckley (CCACT Board President), Her Excellency Mrs Linda Hurley, His Excellency, General the Honourable David Hurley AC DSC (Retd), CCACT CEO Verity Hawkins.

President's Foreword

With disruption and change comes opportunity and achievement. This has been reflected in the way Cancer Council ACT continues to strive every minute, every hour, every day to deliver essential support services, prevention programs and research funding to Canberra and the surrounding community.

This past financial year, Cancer Council ACT began a steady return to in person events and services, with 395 instances of cancer support provided, 48 education programs delivered, and 796 community members engaged in our fundraising campaigns.

For all this we thank our donors, our volunteers, community fundraisers, and countless other stakeholders. It is your dedication that enables us to support those impacted by cancer in our community at a time when they really need us.

Verity Hawkins has seen her first year as CEO at Cancer Council ACT and has worked diligently with the board and team to develop a strategic plan, providing a strong direction for the organisation moving forward. As we focus on stronger community engagement, we will see greater awareness of our services and programs, as well as new developments and trusted advocacy to best meet the needs of our community in an effective and transparent way.



I would like to acknowledge the planning, hard work and flexibility of the Cancer Council ACT staff, many of whom are new to the team. They have ensured that our services, programs, and events continued to be delivered throughout the pandemic and that they are adaptable to changing circumstances for the future.


Finally, I would like to express our gratitude for the ongoing dedication and support of our Patron, Her Excellency Mrs Linda Hurley. I extend this gratitude to our new ambassadors, Miss Galaxy Australia Emily Egan who is the SunSmart ambassador, and Sharon Young, Wig Service ambassador, all of whom play an important role in helping to share our message across the Canberra region.

ROGER BUCKLEY President

MEET THE BOARD



Mr Roger Buckley Board President, Cancer Council Australia Board Director



Mr Phil Greenwood Board Vice-President, Finance Risk and Audit Committee Member



Mr Howard Pickrell Board Treasurer, Finance Risk and Audit Committee Chair



Professor Paul Craft Board Honorary Sectretary, Research Commitee Chair



Ms Christine Brill Board Director, Finance Risk and Audit Committee Member



Ms Anne Kingdon Board Director, Governance Committe Chair



Mr Ardi Karchu Board Director, Governance Committee Member



Dr Denise Kraus Board Director, Governance Committee Member



Mr Allistar Twigg Board Director until February 2022





CEO REPORT

The 2021-22 Annual Report marks my first year at the helm of Cancer Council ACT. On reflection, it has been a wonderful first year, and I am excited to have been part of our effective return to face-to-face program and service delivery as we all continue to adapt and shift into a new phase of the COVID-19 pandemic.

Our achievements delivered in 2021-22 are documented in this report, but among them include:

We saw 43 people receive post cancer treatment support through our new ENRICHing survivorship program.

We provided \$130,000 in research grant funding to two local research teams who are targeting bowel cancer and chemotherapy impacts.

We reached 1192 people through education sessions, prevention programs and cancer information.

None of this would be possible without the support of our donors, volunteers, partners, and the ACT community, who have continued to support us through Daffodil Day, Australia's Biggest Morning Tea and Relay for Life.

Over the next 12 months, I look forward to continuing to develop our connections within the community as we strengthen our engagement and service delivery to best support the needs of those impacted by cancer here in Canberra.

IN MEMORY

We acknowledge with regret the death of the following contributors to Cancer Council ACT during the past year and wish to extend our condolences and thanks to their families.

Dr David Leong MBBS, FRACP (November 2021) | Associate Professor James D'Rozario MBBS, FRACP, FRCPA (January 2022)

Dr Edward (Ted) Fleming MBBS FRACS (November 2021) | Mr Alan Foskett OAM (January 2022) | Dr Katherine (Kate) Hannan (March 2022)



Thank you to Subaru Canberra for our Daffodil Car, that helps us deliver cancer support services and prevention programs across the ACT and surrounds.

STRATEGIC PLAN 2022-25

Our vision	A cancer free future
Our purpos	To alleviate the impact of cancer in our community
Our values	Accountability Honesty Empathy Good Intent
Our priorit	ies
000 Collaboration	Our work will be underpinned by the voice of the ACT community, clients and carers, volunteers, health professionals, academics, and key policy and funding decision makers. We will build strong relationships, leverage partnerships, and proactively engage with our stakeholders.
Awareness and Support	We will provide support for all those who are navigating the cancer system and will promote cancer awareness including prevention practices across the community. We will ensure our services are effectively promoted so that we reach and support more people.
Financial Stability	We will drive financial sustainability, revenue growth and diversification including using innovative approaches. We will ensure a focus on efficiency, transparency, and return on investment to enable stronger service delivery.
Services	We will ensure our support, prevention and information services meet the needs of the community. We will continually revisit and test service delivery models to ensure they are maximising outcomes and will aspire to pursue development of new services to fill identified gaps.
<u>b</u> Research	We will proactively pursue opportunities to contribute to ACT-based cancer research. We will look for ways to share our knowledge, experience, and promote the work of our research grant beneficiaries.
Advocacy	We will be a trusted voice for cancer patients and carers. We will advocate to strengthen our impact in collaboration with the community, our beneficiaries and decision makers, giving a voice to the ACT.

KEY 2021-22 HIGHLIGHTS



NEW PROGRAM

Introduced the ENRICHing Survivorship program



UPGRADES

Upgrades to the Wig Service – more modern styles – including more options for men; more products, including SunSmart hats and sunglasses; and our very own Wig Ambassador

CLIENT SERVICES

The Client Services Team at CCACT strives to deliver support, prevention and information services that meet the needs of the community, as well as to coordinate support for cancer research. CCACT does this through our 13 11 20 free, confidential telephone information and support service, our SunSmart and tobacco cessation prevention programs and our Wig Service. We also administer the issuance of two grants supporting cancer research in the ACT.



BOOST

Upgrades to our 13 11 20 phone system for COVID-proofing, with hire of oncology experienced operators



ENGAGEMENT

Strengthened engagement with government sectors for cancer education programs





ENRICHING SURVIVORSHIP

The ENRICHing Survivorship program is an ACT Health funded program. Each program consists of a free 8-week session that aims to restore physical and emotional wellbeing after cancer treatment through sessions on exercise and nutrition, peer support and yoga and mindfulness.

Three rounds of ENRICHing Survivorship programs have been run in the 2021-22 year reaching 43 participants, with a further 4 sessions planned for 2022-23. The feedback on this program has been very positive.



Thank you to Arthritis Australia, Space 42 and all our facilitators.

INFORMATION & SUPPORT

Cancer Council 13 11 20 is a free, confidential telephone information and support service for people impacted by cancer, including family and friends. Through this service our professional healthcare staff answer questions about all aspects of cancer, including prevention, early detection and treatment. They also assist with practical and emotional support as well as referring to appropriate services in the area.



COMMUNITY SUPPORT

Cancer Support sessions

24 Cal

9795

Cancer Support forums

> Brochures provided



WIG SERVICE

The Cancer Council ACT Wig Service saw 81 clients and provided 230 items of headwear such as wigs, turbans, hats, and beanies for people who have experienced hair loss due to cancer treatment in the ACT. This service is supported by our wonderful volunteers, who contributed 139 hours this financial year.

Headwear items provided: 230

Volunteer hours contributed: 139

SHARON YOUNG -WIG SERVICE AMBASSADOR

Sharon was diagnosed with Hodgkin's Lymphoma in late 2021 after finding a fast-growing lump on her neck. As a result of her chemotherapy treatment, Sharon experienced hair loss and was interested in having wigs as an option. She contacted Cancer Council ACT, booked an appointment with our client services team and was delighted with the whole experience. Sharon shares her cancer journey and stylish wigs across her popular social media platforms to support the journey of others going through similar experiences.

"I knew I wanted grey and thought that there wouldn't be much in my style - that there would be more older-looking styles. I felt genuine excitement when I knew I had found the one! I've had so many compliments."



Cound ICT

PREVENTION: SUNSMART

The SunSmart program aims to reduce skin cancer in the ACT

Ultraviolet (UV) radiation exposure varies throughout the year and CCACT is leading the conversation for a balance between the benefits and harms of exposure and the links with vitamin D.

The SunSmart Schools Program has awarded SunSmart status to 99 Schools and early learning centres in the ACT, with 5 new and 19 reviews this financial year. Using current schools census and childcare enrolments data, this equates to 44,356 ACT primary students, and 15,000 childcare attendees protected by nationally recognised UV policies and procedures.



The SunSmart professional learning platform is continuously marketed to schools and childcare centres to increase the competency and capacity for teachers and staff to fulfill the requirements of approved UV protection policies and procedures. This strategy has proven incredibly successful, with 346 unique completions of the online modules during the reporting period.

CCACT has increased the range of presentations available to the ACT community. This was designed to cater for a wider audience. Available now are UV masterclass for educators, SunSmart toolbox talk for outdoor workers, UV presentation for outdoor workers, and a UV protection session for early learning centre (ELC) children. CCACT delivered a total of 14 UV protection presentations during this reporting period.

Several of our usual community events were impacted by COVID-19 restrictions. Despite this Sid the Seagull was able to get out and about for National Skin Cancer Action Week to remind Canberrans to be SunSmart in November 2021. Cancer Council ACT also engaged with the community through our two Canberra show stalls in February 2022 with information, free sunscreen, and an appearance from Sid.

99

Schools registered for SunSmart schools' program

5

NEW Schools registered for SunSmart schools' program

19

Schools had their SunSmart review

346

SunSmart professional learning modules undertaken

16

SunSmart masterclasses provided

2094

SunSmart newsletter subscribers – 2094 (302 workers, 517 schools, 354 secondary schools)

SunSmart education sessions delivered to schools and workplaces





HEALTHY LIFESTYLE

CCACT promotes a healthy lifestyle through the provision of information on our website, across our social media channels and through local media. CCACT worked with Canberra Weekly on a healthy lifestyle series that was published digitally and in print across four weeks in December and January.

EMILY EGAN – SUNSMART AMBASSADOR, MISS GALAXY AUSTRALIA

At 22 years Emily had her skin checked after seeing a Cancer Council skin care advertisement. When her doctor required her to have a suspicious mole under her chin removed, Emily took this as a wakeup call to encourage her friends to get their skin checked too. Now, as an avid sunscreen wearer, Emily helps Cancer Council ACT spread the message of sun protection and skin cancer checks as our SunSmart Ambassador. Since winning the title of Miss Galaxy Australia Emily has used her position to promote the importance of sun protection across various media opportunities and is making the most of her title to fundraise for Cancer Council ACT.





TOBACCO CESSATION

CCACT conducts smoking and vaping prevention and cessation programs and guidance to smokers and vapers in the general community and workplaces and delivers training to relevant personnel (including general practitioners and pharmacists) to build capacity in the community.

CCACT delivered 15 educations sessions and 3 healthcare training sessions that are designed to build the capacity and competence of hospital healthcare staff, workplaces, and community service organisations to deliver brief interventions for staff and community members at varying stages of readiness to quit smoking and to refer to appropriate 'quit' services.

CCACT provided education to Bunnings Fyshwick staff and clients as part of a 'World No Tobacco Day' in-store event promoting smoking cessation and information on support services. Other education sessions with partnered community service organisations such as WellWays, Toora Women Inc., and Ted Noffs Foundation were conducted, as well as to Transport Canberra, Roads ACT and Canberra PCYC. Cancer Support Coordinator Alex Dreyer hosting a tobacco cessation stall at Bunnings Fyshwick



Education sessions







Brief interventions

TACKLING TOBACCO

Tackling Tobacco is an ACT Health funded program that seeks to change the culture of an organisation to a non-smoking environment, encouraging their staff and clients to commence thinking about or actively quitting smoking. CCACT staff have undergone extensive training (under the guidance of Cancer Council NSW) to enable them to now train external organisation staff and clients in tobacco cessation skills. CCACT have already onboarded two organisations and will look to bring on more, now that staff are fully trained.

RESEARCH

One of the pillars of Cancer Council ACT is the support of cancer research. Cancer Council ACT is committed to funding local research on all aspects of cancer, including cancer prevention, detection and treatment, as well as understanding and improving the emotional (psychological) and social impact of the disease.

In May of 2022, CCACT announced two recipients for the Research Grant program at a special morning tea event hosted by Her Excellency Mrs Linda Hurley. This year these grants have been awarded to Dr Anukriti Mathur and team, and Dr Rita Ferreira and team, both from the John Curtin School of Medical Research, Australian National University (ANU).



Dr Mathur's project is investigating the role of immune proteins in preventing and protecting against bowel cancer. Findings from this study will help to generate new diagnostic screening tools and immunotherapies for cancer.

Dr Ferreira's project will explore the use of new and effective anti-cancer drugs to help prevent the reduction of blood platelet numbers caused by chemotherapy and allow cancer treatments to continue, improving outcomes and quality of life for patients.

CANCER COUNCIL ACT PATHOLOGY PRIZE WINNER

Dr Rita Ferreira

In December 2021 CCACT, in conjunction with The Academic Unit of Pathology at the ANU Medical School, awarded the 'Cancer Council ACT Pathology Prize Year Four' to students Gemma Buttigieg and Ky Ruprecht, who showed an outstanding response to the pathology question in the Year Four examination that reflected their comprehensive knowledge and application of pathology issues.





Ky Ruprecht, Professor Jane Dahlstrom and Gemma Buttigieg

FUNDRAISING AND MARKETING

Cancer Council ACT relies on the generosity of the community to help raise much needed funds for our education and prevention programs, support services and funding of local cancer research.

Cancer Council ACT has a range of fundraising options throughout the year including events, appeals, and peer-to-peer activities. Whilst COVID-19 restrictions continued to impact how these were delivered, the Canberra community showed their support for the modified versions of these much-loved events and campaigns.

DAFFODIL DAY

Daffodil Day 2021 was quickly turned around when Canberra entered its second lockdown in August 2021 and Mix 106.3 took to the drive thru to help deliver flowers, contact-free, to the community, helping to raise \$38,687.



AUSTRALIA'S BIGGEST MORNING TEA

Australia's Biggest Morning Tea 2022 saw 219 hosts bring their communities together to raise a cup and raise \$131,282 for cancer right here in Canberra.



THE LONGEST DAY

The Longest Day 2021 was able to go ahead as the golf clubs started to reopen and we saw 13 teams of 49 participants raise \$32,433.



RELAY FOR LIFE

Relay For Life was back on the track in 2022 with 500 people coming together to walk for 10 hours for this one-day event at the AIS athletics track. Together with all the schools who hosted a Relay Your Way event on their campus, \$263,108 was raised to support those impacted by cancer in our community.



THE MARCH CHARGE

The March Charge 2022 had Canberrans put their best foot forward and walked or ran throughout the month of March to raise \$29,640 for cancer research.

DO IT FOR CANCER

Do It For Cancer runs all year round, giving people the opportunity to host their own fundraiser in their own way. We had 28 amazing people host a fundraiser this financial year – from head shaves to sports events to girls' nights in – together you raised \$51,065 for cancer prevention, support, and research.





Ben's mates raised over \$16,000 when they all shaved their heads to support Ben

Cancer Council ACT runs appeals throughout the year during Christmas, Tax Time and Daffodil Day. Thanks to the generosity of our community, we raised over \$57,000 through these appeals this financial year.



WORLD CANCER DAY

World Cancer Day was on 4 February, with the theme for 2022 'Close the care gap' recognising inequities in cancer care. For the ACT this highlighted the care gaps throughout COVID-19 restrictions and measures.



The Bold Bandannas: (Team Captain Rosemary Drabsch pictured here) achieved Top Fundraiser at Relay again this year, dedicating themselves to raise over \$63,000, with a big portion from sales of their homemade goods



Relay For Life motivated Penny through her cancer treatment

FINANCIAL REPORT

Report of the Directors	17
Director's Declaration	21
Independent Auditor's Report	22
Statement of Profit or Loss and Other Comprehensive Income	24
Statement of Financial Position	25
Statement of Changes in Equity	26
Statement of Cash Flows	26
Notes to the financial Statements	27

Report of the Directors

Your directors present their report with respect to the result of the company for the year ended 30 June 2022 and the state of the company's affairs at that date.

DIRECTORS

The following persons held office during the year ended 30 June 2022 or to the date in this report:

Director	Date of Appointment, Occupation, and Other Directorships	Responsibility
Mr Roger Buckley JP BBA, MC	Appointed: 9 May 2016 Occupation: Company Secretary – Adria Village; Sole Trader – Registered Marriage Celebrant Director – Cancer Council Australia Member – Australian Federation of Civil Celebrants Member – Cancer Council Chairs Forum	President Board Nominee
Mr Phil Greenwood JP	Appointed: 20 March 2018 Occupation: Retired CEO Other Directorships: Director Rotary Club Tuggeranong, Trust Fund and Probus	Vice President Board Nominee
Dr Paul Craft MBBS, MPH, FRACP	Appointed: 3 July 2013 Occupation: Medical Oncologist, the Canberra Hospital; Associate Professor Medical Oncology, ANU Medical School; Clinical Director, Cancer and Ambulatory Support, Canberra Hospital	Honorary Secretary Board Nominee
Mr Howard Pickrell B Sci Agriculture; Chartered Accountant (CA)	Appointed: 21 February 2017 Occupation: Chief Operating Officer, Australian Christian Lobby Ltd Other Directorships: Nil	Treasurer Board Nominee
Ms Christine Brill JP (ACT) Grad Cert Mgt, Grad Dip Empl Rel M.HRM, FSAE, FAHRI, AFACHSM, MAICD	Appointed: 20 September 2001 Occupation: Executive Officer, Doctors Health Services, Australian Medical Association	Board Nominee
Mr Allistar Twigg RFD, B ECON, LLB,	Appointed: 18 February 2016 Resigned: 7 February 2022 Occupation: Lawyer Other Directorships: Non-executive Director of Profession of Independent Financial Advisers Ltd	Board Nominee.
Mr Ardi Kachru	Appointed: 21 November 2019 Occupation: Assistant Director of Marketing, Department of Veteran' Affairs Other Directorships: Nil	Board Nominee
Dr Denise Kraus	Appointed: 21 November 2019 Occupation: General Practitioner (FRACGP) Other Directorships: Nil	Board Nominee
Ms Anne Kingdon	Appointed: 21 November 2019 Occupation: Retired Lawyer Other Directorships: Secretary - Tuross Heads Rural Fire Service	Board Nominee

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated above.

During the financial year, seven meetings of directors were held. The number of meetings attended and number of meetings eligible to attend were:

Mr Roger Buckley Mr Phil Greenwood	7 7	7
Mr Phil Greenwood	7	6
		0
Dr Paul Craft	7	7
Mr Howard Pickrell	7	7
Ms Christine Brill	7	6
Mr Allistar Twigg	4	3
Mr Ardi Kachru	7	6
Dr Denise Kraus	7	7
Ms Anne Kingdon	7	7

COMPANY SECRETARY

Kata Andric was Company Secretary from 1 July 2021 until the AGM on 23 November 2021, when Verity Hawkins was appointed to the position.

ACTIVITIES

The principal activities of the company were to provide cancer information, support and prevention services.

RESULTS AND REVIEW OF OPERATIONS

The net result of operations of the company was an operating deficit of \$281,805 (2020-21: \$471,478 surplus).

STATE OF AFFAIRS

There was no significant change in the state of affairs of the company during the financial year.

OBJECTIVES AND STRATEGIES

Long and short term objectives of the entity;

The long-term objective of The Cancer Council ACT is to decrease the incidence and impact of cancer in the ACT.

The short-term objectives are directed towards funding and delivering programs and support that have a tangible impact on people affected by cancer, including cancer education and prevention, support programs, advocacy and provision of local cancer research grants.

Our strategies for achieving those objectives;

Strategies to achieve both short and long-term objectives include using the most appropriate evidence-based activities and tools to ensure the Cancer Council ACT realises its vision of a Cancer Free Future. This includes maintaining a portfolio of fundraising activities which engages those who share our vision, by matching their capacity and motivation to donate revenue. Building and maintaining a diverse range of skills within the Cancer Council ACT's workforce will enable the organisation to continue to deliver high quality services to its clients and customers.

Principle activities during the year and how those activities assisted in achieving objectives;

Cancer Information, Support Services and Supportive Care for cancer patients and those affected by a diagnosis of cancer.

• Telephone information and support (13 11 20) as well as referrals to relevant Cancer Council and external service providers (eg: legal and financial planning referral service). Provision of cancer-related publications, interactive and supportive online services and access to information regarding all cancers via the Cancer Council ACT website.

- Supply of discounted wigs to people losing their hair as a result of their cancer treatment.
- Support groups for people affected by cancer.
- Free education programs including Living With Cancer and the Legal and Financial Matters seminars.

Cancer Prevention and Early Detection Program

- Smoking cessation, education and cancer prevention courses and workshops as well as one-onone interventions to help people quit or not begin smoking at all.
- SunSmart education and skin cancer prevention information provided to early childhood centres, schools (especially primary) and organisations and businesses that have an outdoor workforce.

Research Program

• Provision of funds for cancer research and related projects in the ACT, reviewed (and Board approved), annual cancer research grants.

Fundraising and Business Development Program

• The planning, coordination and successful execution of major fundraising campaigns, including Relay For Life, Australia's Biggest Morning Tea, Daffodil Day and other Cancer Council ACT and community-initiated events and activities to support the provision of services to the greater ACT region.

Direct Marketing - donations to support the services provided by Cancer Council ACT.

• The regular giving program encourages individuals to support Cancer Council ACT by making regular donations throughout the year. Direct Marketing appeals also promote consideration of bequests in Wills, to assist in the ongoing provision of Cancer Council ACT community support and education.

COVID-19

The COVID-19 pandemic continued to impact the organisation's ability to provide some services until early in the new year of 2022, when lockdowns ended and in-person events and programs could be resumed. Although now physically back in the office, there continue to be Covid-related disruptions among staff, volunteers and clients and there has been a noticeable drop in consumer confidence in attending major fundraising events such as Relay For Life.

MEASUREMENT AND PERFORMANCE

How CCACT measures its performance, including any key performance indicators used by the entity.

The Cancer Council ACT currently receives one continuing service funding arrangement from ACT Health to assist the provision of cancer information, prevention and support services. The services to the community are also partly funded by the Cancer Council ACT's fundraising initiatives.

For the 12 months ended 30 June 2022, Cancer Council ACT used the Outputs and Performance Indicators required by ACT Health (ACT Government) as minimum performance indicators for the provision of these services. The aim is to exceed any quantitative and qualitative Performance Indicators set, including, for example, the number of hours of support provided, and the number of courses and workshops held. A report is provided to ACT Health every six months.

The company was also the successful recipient of the following three-year grants through The ACT Government's Health Promotion Grants program:

- Tackling Tobacco Program,
- ENRICHing Survivorship Program.

Although won in the 2021 financial year, action on the start of these grants was deferred to the 2021-22 financial year due to unforeseen delays, including the COVID-19 pandemic.

The Cancer Council ACT assesses its overall effectiveness in a number of ways and includes both qualitative and quantitative measures. These include monitoring the number of calls to the 13 11 20 number, wig service referrals and by email and drop-in enquiries. The number of requests for hard copy information and the number of website page hits for specific topics is another measure. General community awareness about Cancer Council ACT is important to ensure those with a diagnosis of cancer and their families know what services are available. Regular engagement with local media, as well as with our following on social media, is helping to boost this awareness and ensuring the organisation remains connected to the broader community.

DIVIDENDS

The company is limited by guarantee and is prohibited by its objects from distributing any surplus to the members. Accordingly no dividend has been paid or declared by the company since the end of the previous financial year and up to the date of this report.

MEMBERSHIP IN THE COMPANY

The company is limited by guarantee. If the entity is wound up, the constitution states that each member is required to contribute a maximum of \$10 each towards meeting any outstanding obligations of the company. At 30 June 2022 the number of members was 17 (2021:18).

EVENTS SUBSEQUENT TO BALANCE DATE

There has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event of a material and unusual nature likely, in the opinion of the directors, to affect substantially the operations of the company, the results of those operations or the state of affairs of the company in subsequent financial years.

DIRECTORS' BENEFITS

Since the end of the previous financial year, no director has received or become entitled to receive a benefit by reason of a contract made by the company or a related corporation with the director or with a firm of which he/she is a member, or with a company in which he/she has a substantial financial interest, except any benefit that may be deemed to accrue by reason of professional costs paid in the ordinary course of business.

INDEMNIFICATION OF OFFICERS OR AUDITORS

Every member of the Board, Auditor, Secretary and other officer for the time being of the company shall be indemnified out of the assets of the company against any liability arising out of the execution of the duties of their office which is incurred by them in defending any proceedings, wheather civil or criminal, in which judgement is given in their favor or in which they are acquitted or in connection with any application under the Law in which relief is granted to them by the Court in respect of any negligence default, breach of duty or breach of trust.

The company has paid a premium during the financial year in respect of an insurance contract insuring the directors and officers against a liability incurred as an officer for the costs of rexpenses to defend legal proceedings.

Signed at Deakin, ACT this 4th day of November 2022 in accordance with a resolution of the Directors.

y Surkle

Directors' Declaration

The Directors of the company declare that:

- 1. The financial statements and notes are in accordance with the Australian Charities and Not-for-profit Comission Act 2012, and
 - a) comply with Division 60 of the Australian Charities and Not-for-profits Regulation 2013, Accounting Standars – Reduced Disclosure Requirements and other mandatory professional reporting requirements; and
 - b) give a true and fair view of the company's financial position as at 30 June 2022 and of its performance for the year ended on that date;
- 2. In the Directors' opinion, there are reasonable grounds to believe that the company will be able to pat its debts as and when they become due and payable.

Signed at Deakin, ACT this 4th day of November 2022 in accordance with a resolution of the Directors.

y Surkles. Director

Directo



INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE CANCER COUNCIL ACT ABN 33 113 296 601

Report on the Audit of the Financial Report

Qualified Opinion

We have audited the financial report of The Cancer Council ACT (the Company), which comprises the statement of financial position as at 30 June 2022, the statement of comprehensive income, the statement of changes in equity and the cash flow statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the directors' declaration for The Cancer Council ACT.

In our opinion, except for the effects on the annual financial report of the matter referred to in the Basis for Qualified Opinion paragraph below the accompanying financial report of the Company is in accordance with the Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012* (ACNC Act), including:

- i. giving a true and fair view of the Company's financial position as at 30 June 2022 and of its financial performance for the year then ended; and
- ii. complying with Australian Accounting Standards Reduced Disclosure Requirements and the Australian Charities and Not-for-profits Commission Regulation 2013.

Basis for Qualified Opinion

As is common for organisations of this type, it was not practical to maintain an effective system of internal control over the completeness of revenues from fundraising activities involving 'agents' that manually collect and submit donor monies to the Company. Accordingly, our audit in relation to revenue collected by agents totaling \$50,702 for the financial year was limited to the amounts recorded as banked by the Company.

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of our report. We are independent of the Company in accordance with the auditor independence requirements of the Australian Charities and Not-for-profits Commission Act 2012 and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 'Code of Ethics for Professional Accountants' (including independence standards) (the "Code") that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Financial Report and the Auditor's Report Thereon

The directors are responsible for the other information. The other information comprises the information included in the Company's annual report for the year ended 30 June 2022 but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report on that fact. We have nothing to report in this regard.

Directors' Responsibility for the Financial Report

The directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards – Reduced Disclosure Requirements and the *Australian Charities and Not-for-profits Commission Act 2012* and for such internal control as the committee determines is necessary to enable the

Synergy Group Audit Pty Ltd

t. (02) 6260 7477 w. synergygroup.net.au a. Ground Floor, 15 National Circuit, Barton, ACT 2600

PO Box 3789 Kingston ACT 2600 ABN 45 104 227 063 AUTHORISED AUDIT COMPANY NO. 301280

A Correspondent member of the Bentleys Network. Bentleys is a network of independent accounting firms located throughout Australia, New Zealand and China that trade as Bentleys. All members of the Bentleys Network are affiliated only and are separate legal entities and not in Partnership. Liability limited by a scheme approved under Professional Standards Legislation.



preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintains professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for the auditor's opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in the auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify the auditor's opinion. Our conclusions are based on the audit evidence obtained up to the date of the auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during the audit.

We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

Eric Hummer Audit Director

ehummer@synergygroup.net.au 0407 486 637

7 November 2022

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2022

	Notes	2022	2021
		\$	\$
Operating revenue	2	1,899,525	2,185,714
Expenses			
Wig merchandise		(3,669)	(2,927)
Employee related costs	4	(1,321,928)	(1,081,874)
Fundraising costs		(120,400)	(114,365)
Research grants		(130,250)	(126,250)
Occupancy costs	4	(104,125)	(108,225)
Other administrative costs	4	(389,419)	(213,051)
Cancer Council Australia membership		(109,371)	(67,574)
Loss on disposal of assets		(2,168)	-
Net (deficit) / surplus for the year		(281,805)	471,448
		(00)	
Total comprehensive income for the year		(281,805)	471,448

The accompanying notes form part of these financial statements.

STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2022

	Notes	2022	2021
		\$	\$
CURRENT ASSETS			
Cash and cash equivalents	5	3,440,417	3,695,165
Receivables	6	231,086	268,077
Wig merchandise		15,063	5,637
Prepayments		38,817	38,748
Total current assets		3,725,383	4,007,627
NON CURRENT ASSETS			
Property, plant and equipment	7	45,735	60,271
Right-of-use assets	8	747,752	811,465
Intangibles		56,330	-
Total non current assets		849,817	871,736
Total assets		4,575,200	4,879,363
CURRENT LIABILITIES			
Payables	9	243,670	210,872
Annual leave provision		48,739	28,470
Lease liability	10	52,125	48,659
Contract liabilities	3	136,341	163,107
Total current liabilities		480,875	451,108
NON-CURRENT LIABILITIES			
Lease liability	10	743,357	795,482
Total non-current liabilities		743,357	795,482
Total liabilities		1,224,232	1,246,590
Net assets		3,350,968	3,632,773
EQUITY			
Retained earnings		3,350,968	3,632,773
Total equity		3,350,968	3,632,773

The accompanying notes form part of these financial statements.

-

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2022

	2022	2021
	\$	\$
RETAINED EARNINGS		
Balance at 1 July	3,632,773	3,161,325
Net (deficit) / surplus for the year	(281,805)	471,448
Balance 30 June	3,350,968	3,632,773

The accompanying notes form part of these financial statements.

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 30 JUNE 2022

OPERATING ACTIVITIESReceipts from donations, special events and other income1,559,3292,052,715Merchandise receipts14,19112,695Grants receipts423,427363,008Interest received6,62710,927Lease interest paid(34,401)(36,075Payments to suppliers and employees(2,100,104)(1,711,569Net cash (used in) / provided by operating activities(130,931)691,701INVESTING ACTIVITIES(23,577)(18,423Purchases of property, plant and equipment(23,577)(18,423Cost of development of intangible asset(56,330)-Proceeds on sale of property, plant and equipment4,750-Net cash used in investing activities(75,157)(18,423FINANCING ACTIVITIES(48,660)(43,704Lease principal repayments(48,660)(43,704Net cash used in financing activities(254,748)629,574Cash and cash equivalents at beginning of year3,695,1653,065,591			2022 \$	2021 \$
Merchandise receipts14,19112,695Grants receipts423,427363,008Interest received6,62710,927Lease interest paid(34,401)(36,075Payments to suppliers and employees(2,100,104)(1,711,569Net cash (used in) / provided by operating activities(130,931)691,701INVESTING ACTIVITIES23,577)(18,423Purchases of property, plant and equipment(23,577)(18,423Cost of development of intangible asset(56,330)-Proceeds on sale of property, plant and equipment4,750-Net cash used in investing activities(75,157)(18,423FINANCING ACTIVITIES(48,660)(43,704Lease principal repayments(48,660)(43,704Net cash used in financing activities(254,748)629,574Cash and cash equivalents at beginning of year3,695,1653,065,591	OPERATING ACTIVITIES		Ŧ	Ŧ
Grants receipts423,427363,008Interest received6,62710,927Lease interest paid(34,401)(36,075Payments to suppliers and employees(2,100,104)(1,711,569Net cash (used in) / provided by operating activities(130,931)691,701INVESTING ACTIVITIES(23,577)(18,423Purchases of property, plant and equipment(23,577)(18,423Cost of development of intangible asset(56,330)-Proceeds on sale of property, plant and equipment4,750-Net cash used in investing activities(75,157)(18,423FINANCING ACTIVITIES(48,660)(43,704Lease principal repayments(48,660)(43,704Net cash used in financing activities(254,748)629,574Cash and cash equivalents at beginning of year3,695,1653,065,591	Receipts from donations, special events and other income		1,559,329	2,052,715
Interest received6,62710,927Lease interest paid(34,401)(36,075Payments to suppliers and employees(2,100,104)(1,711,569Net cash (used in) / provided by operating activities(130,931)691,701INVESTING ACTIVITIESPurchases of property, plant and equipment(23,577)(18,423)Cost of development of intangible asset(56,330)-Proceeds on sale of property, plant and equipment4,750-Net cash used in investing activities(75,157)(18,423)FINANCING ACTIVITIES(48,660)(43,704)Lease principal repayments(48,660)(43,704)Net cash used in financing activities(254,748)629,574Cash and cash equivalents at beginning of year3,695,1653,065,591	Merchandise receipts		14,191	12,695
Lease interest paid(34,401)(36,075)Payments to suppliers and employees(2,100,104)(1,711,569)Net cash (used in) / provided by operating activities(130,931)691,701INVESTING ACTIVITIESPurchases of property, plant and equipment(23,577)(18,423)Cost of development of intangible asset(56,330)-Proceeds on sale of property, plant and equipment4,750-Net cash used in investing activities(75,157)(18,423)FINANCING ACTIVITIES(48,660)(43,704)Lease principal repayments(48,660)(43,704)Net cash used in financing activities(254,748)629,574Cash and cash equivalents at beginning of year3,695,1653,065,591	Grants receipts		423,427	363,008
Payments to suppliers and employees(2,100,104)(1,711,569)Net cash (used in) / provided by operating activities(130,931)691,701INVESTING ACTIVITIESPurchases of property, plant and equipment(23,577)(18,423)Cost of development of intangible asset(56,330)-Proceeds on sale of property, plant and equipment4,750-Net cash used in investing activities(75,157)(18,423)FINANCING ACTIVITIES(48,660)(43,704)Lease principal repayments(48,660)(43,704)Net cash used in financing activities(254,748)629,574Cash and cash equivalents at beginning of year3,695,1653,065,591	Interest received		6,627	10,927
Net cash (used in) / provided by operating activities(130,931)691,701INVESTING ACTIVITIESPurchases of property, plant and equipment(23,577)(18,423)Cost of development of intangible asset(56,330)-Proceeds on sale of property, plant and equipment4,750-Net cash used in investing activities(75,157)(18,423)FINANCING ACTIVITIES(48,660)(43,704)Lease principal repayments(48,660)(43,704)Net cash used in financing activities(254,748)629,574Cash and cash equivalents at beginning of year3,695,1653,065,591	Lease interest paid		(34,401)	(36,075)
INVESTING ACTIVITIESPurchases of property, plant and equipment(23,577)Cost of development of intangible asset(56,330)Proceeds on sale of property, plant and equipment4,750Net cash used in investing activities(75,157)FINANCING ACTIVITIESLease principal repayments(48,660)Net cash used in financing activitiesNet cash used in financing activitiesCash and cash equivalents(254,748)Cash and cash equivalents at beginning of year3,695,1653,065,591	Payments to suppliers and employees		(2,100,104)	(1,711,569)
Purchases of property, plant and equipment(23,577)(18,423)Cost of development of intangible asset(56,330)-Proceeds on sale of property, plant and equipment4,750-Net cash used in investing activities(75,157)(18,423)FINANCING ACTIVITIES(48,660)(43,704)Lease principal repayments(48,660)(43,704)Net cash used in financing activities(254,748)629,574Net movement in cash and cash equivalents(254,748)629,574Cash and cash equivalents at beginning of year3,695,1653,065,591	Net cash (used in) / provided by operating activities		(130,931)	691,701
Purchases of property, plant and equipment(23,577)(18,423)Cost of development of intangible asset(56,330)-Proceeds on sale of property, plant and equipment4,750-Net cash used in investing activities(75,157)(18,423)FINANCING ACTIVITIES(48,660)(43,704)Lease principal repayments(48,660)(43,704)Net cash used in financing activities(254,748)629,574Net movement in cash and cash equivalents(254,748)629,574Cash and cash equivalents at beginning of year3,695,1653,065,591				
Cost of development of intangible asset(56,330)Proceeds on sale of property, plant and equipment4,750Net cash used in investing activities(75,157)FINANCING ACTIVITIESLease principal repayments(48,660)Net cash used in financing activities(48,660)Net cash used in financing activities(48,660)Net movement in cash and cash equivalents(254,748)Cash and cash equivalents at beginning of year3,695,1653,065,591			(23 577)	(18 /23)
Proceeds on sale of property, plant and equipment4,750Net cash used in investing activities(75,157)FINANCING ACTIVITIESLease principal repayments(48,660)Net cash used in financing activities(48,660)Net cash used in financing activities(254,748)629,574Cash and cash equivalents at beginning of year3,695,1653,065,591			, ,	(10,423)
Net cash used in investing activities(75,157)(18,423)FINANCING ACTIVITIES Lease principal repayments(48,660)(43,704)Net cash used in financing activities(48,660)(43,704)Net movement in cash and cash equivalents(254,748)629,574Cash and cash equivalents at beginning of year3,695,1653,065,591			, ,	_
FINANCING ACTIVITIES Lease principal repayments(48,660)(43,704)Net cash used in financing activities(48,660)(43,704)Net movement in cash and cash equivalents(254,748)629,574Cash and cash equivalents at beginning of year3,695,1653,065,591			-	(18.423)
Lease principal repayments(48,660)(43,704)Net cash used in financing activities(48,660)(43,704)Net movement in cash and cash equivalents(254,748)629,574Cash and cash equivalents at beginning of year3,695,1653,065,591			(10,107)	(10,420)
Net cash used in financing activities(48,660)(43,704)Net movement in cash and cash equivalents(254,748)629,574Cash and cash equivalents at beginning of year3,695,1653,065,591	FINANCING ACTIVITIES			
Net movement in cash and cash equivalents(254,748)629,574Cash and cash equivalents at beginning of year3,695,1653,065,591	Lease principal repayments		(48,660)	(43,704)
Cash and cash equivalents at beginning of year 3,695,165 3,065,591	Net cash used in financing activities		(48,660)	(43,704)
	Net movement in cash and cash equivalents		(254,748)	629,574
	Cash and cash equivalents at beginning of year		3,695,165	3,065,591
Cash and cash equivalents at end of year53,440,4173,695,165	Cash and cash equivalents at end of year	5	3,440,417	3,695,165

The accompanying notes form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2022

Note 1: Summary of significant accounting policies

The financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards and interpretations - including simplified disclosures under AASB 1060 issued by the Australian Accounting Standards Board (AASB) and the *Australian Charities and Not-for-profits Commission Act 2012*. The Company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards.

These financial statements are the first general purpose financial statements prepared in accordance with Australian Accounting Standards – Simplified Disclosures. In the prior year the financial statements were general purpose financial statements prepared in accordance with Australian Accounting Standards – Reduced Disclosure Requirements. There was no impact on the recognition and measurement of amounts recognised in the statements of financial position, other comprehensive income and cash flows of the company as a result of the change in the basis of preparation.

Any new Accounting Standards that have been issued but are not yet effective at balance date have not been applied in the preparation of this financial report. The possible impacts of the initial implementation of these Accounting Standards have not been assessed.

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in financial statements containing relevant and reliable information about transactions, events and conditions. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless stated otherwise.

The financial statements, except for the cash flow information, have been prepared on an accruals basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected noncurrent assets, financial assets and financial liabilities. The amounts presented in the financial statements have been rounded to the nearest dollar.

The financial report of the Company was authorised for issue on the date of signing of the attached Directors' Declaration by the directors.

(a) Income tax

The Company is income tax exempt as a health promotion charity under the *Income Tax Assessment Act* 1997.

(b) Inventories

Wig merchandise is measured at the lower of cost and net realisable value. Costs are assigned on a first-in first-out basis.

(c) Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2022

Note 1: Summary of significant accounting policies (continued)

(c) Financial Instruments (cont'd)

Financial assets:

Financial assets are classified, at initial recognition, as subsequently measured at amortised cost, fair value through other comprehensive income (OCI), or fair value through profit or loss. The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Company's business model for managing them. The Company measures financial assets at amortised cost if both of the following conditions are met:

• The financial asset is held within a business model with the objective to hold financial assets in order to collect contractual cash flows, and;

• The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

The Company's current financial assets are all classified at amortised cost and there has been no been no change in the classification of financial assets from prior years.

Financial assets at amortised cost are subsequently measured using the effective interest (EIR) method and are subject to impairment. Gains and losses are recognised in profit or loss when the asset is derecognised, modified or impaired.

Financial Liabilities

Financial liabilities are initially measured at the transaction price. Financial liabilities are subsequently measured at amortised cost using the effective interest rate method or at fair value through profit and loss. Trade and other payables are measured at amortised cost.

(d) Property, plant and equipment

Each class of property, plant and equipment is carried at cost less, where applicable, any accumulated depreciation or impairment write-offs. The carrying amount of property, plant and equipment is reviewed annually by the Company to ensure it is not in excess of the remaining service potential of these assets. All classes of property, plant and equipment are depreciated using the straight line or diminishing balance methods. Depreciation is charged at the following rates:

Furniture and equipment	20% straight line
Computer equipment	37.5% straight line
Motor vehicles	22.5% diminishing balance
Right of Use Assets	Lease term 6.67% (15 years)

(e) Employee benefits

Short-term employee benefits

Provision is made for the Company's obligation for short-term employee benefits. Short-term employee benefits are benefits (other than termination benefits) that are expected to be settled wholly within 12 months after the end of the annual reporting period in which the employees render the related service, including wages, salaries and annual leave. Short-term employee benefits are measured at the (undiscounted) amounts expected to be paid when the obligation is settled. Based on past experience, the Company does not expect the full amount of annual leave balances classified as current liabilities to be settled within the next 12 months. However, these amounts must be classified as current liabilities since the Company does not have an unconditional right to defer the settlement of these amounts in the event employees wish to use their entitlement. The Company's obligations for short-term employee benefits such as wages and salaries are recognised as a part of current trade and other payables in the Statement of Financial Position.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2022

Note 1: Summary of significant accounting policies (continued)

(e) Employee benefits (continued)

Other long-term employee benefits

The Company classifies employees' long service leave entitlements as other long-term employee benefits as they are not expected to be settled wholly within 12 months after the end of the annual reporting period in which the employees render the related service. Provision is made for the Company's obligation for other long-term employee benefits, which are measured at the present value of the expected future payments to be made to employees to the extent that they are not funded by the ACT Community Sector Portable Long Service Leave Scheme. Expected future payments incorporate anticipated future wage and salary levels, durations of service and employee departures, and are discounted at rates determined by reference to market yields at the end of the reporting period on government bonds that have maturity dates that approximate the terms of the obligations. Upon the remeasurement of obligations for other long-term employee benefits, the net change in the obligations is recognised in profit or loss classified under employee benefits expense.

The Company's obligations for long-term employee benefits are presented as non-current liabilities in its statement of financial position, except where the Company does not have an unconditional right to defer settlement for at least 12 months after the end of the reporting period, in which case the obligations are presented as current liabilities.

Retirement benefit obligations

Defined contribution superannuation benefits

All employees of the Company receive defined contribution superannuation entitlements, for which the Company pays the fixed superannuation guarantee contribution (currently 10% of the employee's average ordinary salary) to the employee's superannuation fund of choice. All contributions in respect of employee's defined contributions entitlements are recognised as an expense when they become payable. The Company's obligation with respect to employees' defined contribution entitlements is limited to its obligation for any unpaid superannuation guarantee contributions at the end of the reporting period. All obligations for unpaid superannuation guarantee contributions are measured at the (undiscounted) amounts expected to be paid when the obligation is settled and are presented as current liabilities in the Company's Statement of Financial Position.

(f) Cash and cash equivalents

Cash and cash equivalents include cash on hand and deposits held at call with banks or financial institutions.

(g) Research grants

Research grants are recognised as expenses at the time the funds are disbursed to the research body. Research grants that have been contracted but not yet paid are disclosed as commitments payable.

(h) Revenue recognition

Goods and services

Revenue from the sale of merchandise is recognised upon delivery of the goods to customers (point in time). Revenue from the rendering of a service is recognised upon the delivery of the service to the customers (point in time).

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2022

Note 1: Summary of significant accounting policies (continued)

Special events, donations, bequests and membership fees

Donations, bequests and membership fees are recognised as income when received except where for amounts receivable from other State Cancer Council's where an existing arrangement is in place that establishes an entitlement to the monies receivable which are recognised when the right to receive the contributions is confirmed.

Grants and Government Assistance

Where performance obligations for the grants and other government assistance are not sufficiently specific, the Company recognises revenue when it gains control of (or has the right to receive) the asset (cash), within the scope of AASB 1058 *Income for Not-for-Profit Entities.*

Where a grant is subject to specific performance obligations and conditions that must be satisfied by the Company, revenue is recognised in the period in which contract costs are incurred for which the government funding is intended to compensate provided all attaching conditions have been complied with and the performance obligations under the contract have been met (within the scope of AASB 15 *Revenue from Contracts with Customers*). Revenue received where the cost to which it relates has not yet been incurred is deferred by recognition of a contract liability in the Statement of Financial Position.

Fundraising events

Revenue and costs from fundraising events that have a specific performance obligation are recognised as revenue and expense on completion of the event (point in time). Income received and expenses incurred prior to event are recognised as income in advance (liabilities, unearned revenue) and prepayments (other current assets) respectively.

Interest income

Interest income is recognised on a proportional basis taking into account the interest rates applicable to the financial assets.

Dividend and royalty income

Dividend and royalty income is recognised when received.

(i) Goods and Services Tax

All revenue and expenses are stated net of the amount of goods and services tax (GST).

(j) Impairment

At each reporting date, the Company's directors review the carrying values of its assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use, is compared to the asset's carrying value. As a not-for-profit entity, value in use, according to AASB 136 Impairment of Assets, is depreciated replacement cost. Any excess of the asset's carrying value over its recoverable amount is expended to the Statement of Profit or Loss and Other Comprehensive Income.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2022

Note 1: Summary of significant accounting policies (continued)

(k) Critical accounting judgement and estimates

The directors evaluate estimates and judgements incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the Company.

Key Estimates - Impairment

The Company assesses impairment at each reporting date by evaluating conditions specific to the Company that may lead to impairment of assets. Should an impairment indicator exist, the determination of the recoverable amount of the asset may require incorporation of a number of key estimates. No impairment indicators were present at 30 June 2022.

Key judgements - Performance obligations under AASB 15

To identify a performance obligation under AASB 15, the promise must be sufficiently specific to be able to determine when the obligation is satisfied. Management exercises judgement to determine whether the promise is sufficiently specific by taking into account any conditions specified in the arrangement, explicit or implicit, regarding the promised goods or services. In making this assessment, management includes the nature / type, cost/ value, quantity and the period of transfer related to the goods or services promised.

Key judgements - Significant judgement in determining the lease term of contracts with renewal options

The Company determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised.

The Company applies judgement in evaluating whether it is reasonably certain to exercise the option to renew. That is, it considers all relevant factors that create an economic incentive for it to exercise the renewal. After the commencement date, the Company reassesses the lease term if there is a significant event or change in circumstances that is within its control and affects its ability to exercise (or not to exercise) the option to renew.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2022

Note 1: Summary of significant accounting policies (continued)

(I) Leases

Set out below are the new accounting policies of the company upon adoption of AASB 16:

Right-of-use assets

The Company recognises right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognised right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Right-of-use assets are subject to impairment.

Lease liabilities

At the commencement date, the Company measures lease liabilities measured at the present value of the lease payments unpaid at that date. The lease payments include fixed payments (including in substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees.

In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. When the lease liability is remeasured, the corresponding adjustment is reflected in the right-of-use asset, or profit and loss if the right-of-use asset is already reduced to zero.

(m) Comparative information

Where necessary, comparative figures have been adjusted to conform to changes in presentation in this financial report.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2022

NOTES TO THE FINANCIAL STATEMENTS FO			2022	2021
			\$	\$
Note 2: Revenue				·
Revenue from contracts with customers				
Grants		3	379,933	325,007
Online retail sales			12,245	8,798
Wig service			656	2,744
Other products and services			10,196	10
Total revenue from contracts with customers		-	403,030	336,559
Other income Donations			678,170	922,055
Special events			574,236	613,974
Interest			6,627	10,927
Royalties			47,475	39,148
COVID-19 Government assistance			-	91,500
Bequests			187,388	170,565
Membership fees			382	986
Profit on sale of assets			2,217	-
Total other income		-	1,496,495	1,849,155
Total revenue		-	1,899,525	2,185,714
Revenue from contracts with customers Timing of revenue - At a point in time				
Grants		3	74,037	-
Online retail sales			12,245	8,798
Wig service			656	2,744
Other products and services		_	10,196	10
Total revenue from contracts with customers		-	97,134	11,552
Timing of muchanics Over time				
Timing of revenue - Over time Grants		3	305,896	325,007
Grands			305,896	325,007
		-	000,000	020,007
Note 3: Grants revenue and contract liabilities				
Funding body:	Unexpended funds at 30 June 2021	Grants funding received	Grants recognised as revenue	Unexpended funds at 30 June 2022
ACT Health:				•
	\$	\$	\$	\$
 Cancer Support Service, SunSmart & Smoking Cessation 	\$ -	\$ 332,645	\$ 305,896	\$ 26,749
 Cancer Support Service, SunSmart & Smoking Cessation Tackling Tobacco in the ACT 	\$ - 129,100			
Smoking Cessation	-		305,896	26,749

All amounts in the table above are exclusive of GST.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2022

NOTES TO THE FINANCIAL STATEMENTS FOR THE TEAR ENDED 30 JUNE	2022	2021
	\$	\$
Note 4: Expenses	Ŧ	Ŧ
Expenses include the following:		
Depreciation of non-current assets:		
 computer equipment, furniture, plant and equipment (Other administrative costs) 	32,878	31,432
 motor vehicles (Other administrative costs) 	533	890
 right-of-use assets (Occupancy costs) 	63,713	61,677
Total depreciation	97,124	93,999
 Employee related costs: ▶ salaries, wages and workers compensation 	1,080,923	979,352
 recruitment costs and professional development 	103,181	37,856
 defined contribution superannuation plan 	100,341	84,700
 movements in employee provisions 	34,463	(20,034)
► contract staff and labour hire	3,020	-
Total employee benefits	1,321,928	1,081,874
Note 5: Cash and cash equivalents		
Cash on hand	-	850
Cash at bank	3,419,146	3,673,044
Deposits at call	21,271	21,271
	3,440,417	3,695,165
Note 6: Receivables		40.000
Trade debtors	-	16,632
Amounts receivable from related party - Cancer Council Australia	130,079	159,422
Amounts receivable from related party - Cancer Council New South Wales	59,209	87,438
Amounts receivable from related party - Cancer Council Victoria	1,533	2,313
Other receivables Other receivables - GST	5,498	-
Other receivables - GOT	34,767	2,272
	231,086	268,077

No impairment indicators were present in respect of receivables at 30 June 2022 or 30 June 2021.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2022

			2022	2021
			\$	\$
Note 7: Property, plant and equipment				
Furniture, plant and equipment – at cost			90,922	117,866
Accumulated depreciation			(68,842)	(76,746)
		-	22,080	41,120
Motor vehicles – at cost			-	22,484
Accumulated depreciation			-	(19,417)
		-	-	3,067
Computer Equipment - at cost			170,120	149,877
Accumulated depreciation			(146,465)	(133,793)
		-	23,655	16,084
Total Property, Plant and Equipment		-	45,735	60,271
(a) Movement in the carrying amounts for each class of property, plant and equipment between the beginning and the end of the current financial year	Computer Equipment	Furniture, plant and equipment	Motor vehicles	Total
	\$	\$	\$	\$

	\$	\$	\$	\$
Balance at 1 July 2021	16,084	41,120	3,067	60,271
Additions	23,142	435	-	23,577
Disposals	(235)	(1,932)	(2,534)	(4,701)
Depreciation expense	(15,336)	(17,542)	(533)	(33,411)
Balance at 30 June 2022	23,655	22,080	-	45,735

	2022	2021
	\$	\$
Note 8: Right-of-use assets		
Office lease and photocopier	934,762	934,762
Accumulated depreciation	(187,010)	(123,297)
	747,752	811,465
(a) Movement in the carrying amount of right-of-use assets between the beginning and the end of the current financial year	Right of Use Asset	Total
Balance at 1 July 2021	811,465	811,465
Depreciation expense	(63,713)	(63,713)
Balance at 30 June 2022	747,752	747,752

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2022

	2022 \$	2021 \$
Note 9: Payables	Ψ	φ
CURRENT		
Unsecured liabilities:		
Employee benefits payable	61,435	35,721
Other creditors and accrued expenses	51,105	70,546
Amounts payable to related parties (Note 13)	127,510	101,895
Portable long service leave liability	3,620	2,710
	243,670	210,872
Note 10: Lease liability		
CURRENT		
Lease liability - Office lease and photocopier	52,125	48,659
	52,125	48,659
NON-CURRENT		
Lease liability - Office lease and photocopier	743,357	795,482
	743,357	795,482

At balance date, the Company has remaining lease commitments payable of \$795,483 in respect of the above office and photocopier leases.

The future minimum lease payments arising from the Company's lease contracts at the end of the reporting period are as follows:

Lease principal

no later than one year	52,124	48,659
later than one year but no later than 5 years	313,874	296,239
► later than 5 years	429,484	499,243
	795,482	844,141

Note 11: Company Details

(a) Location
 The registered office and principal place of business of the Company is:
 The Cancer Council ACT Limited
 Unit 1, 173 Strickland Crescent
 Deakin ACT 2600

(b) Activities

The Company operates in the Canberra and surrounding region providing cancer support services.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2022		
	2022	2021
	\$	\$
Note 12: Compensation of Key Management Personnel		
The aggregate compensation of the key management personnel of the Company executives, is set out below:	, including direct	ors and
Short-term employee benefits	185,151	125,384
Post-employment benefits	18,136	16,139
Other long-term benefits	2,889	1,564
Termination benefits	-	79,088
Total compensation	206,176	222,175

NOTES TO THE EINANCIAL STATEMENTS FOR THE YEAR ENDED 20, HINE 2022

The directors did not receive any remuneration directly or indirectly from the Company or any related body corporate for management of the Company, other than reimbursements of expenses incurred on behalf of the Company. This compensation is included in the Statement of Profit or Loss and Other Comprehensive Income under the category of employee benefits expense.

Note 13: Related Party Transactions

All transactions during the year were on normal commercial terms and conditions unless otherwise stated.

► The Company is a member of and has a common director with Cancer Council Australia. The Company and other membership organisations in each state and territory contribute annual membership fees, purchase fundraising merchandise and receive net fundraising income from Cancer Council Australia.

Note 14: Financial Risk Management

The Company's principal financial instruments comprise cash at bank, receivables and accounts payable. These financial instruments arise from the operations of the Company.

The carrying amounts for each category of financial instruments, measured in accordance with AASB 9 as detailed in the accounting policies to these financial statements, are as follows:

Financial Assets

Financial assets at amortised cost:		
Cash and cash equivalents	3,440,417	3,695,165
Receivables	231,086	268,077
Total Financial Assets	3,671,503	3,963,242
Financial Liabilities		
Financial liabilities at amortised cost:		
Payables	243,670	210,872
Lease liabilities	795,482	844,141
Total Financial Liabilities	1,039,152	1,055,013
Note 15: Auditors Remuneration		
Remuneration of the Auditor for:		
Auditing of the financial report	12,050	11,500
Compilation of the financial report	2,070	1,950
	14,120	13,450

Note 16: Subsequent Events

The financial report of the Company was authorised for issue on the date of signing of the attached Directors' Declaration by the directors.

THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK.

How you can help

Give Regularly

A little goes a long way and adds up over time, when you give regularly. It also gives us confidence to commit to long-term projects.

Host (or join) a fundraising event

Join one of our much loved fundraising events such as Daffodil Day, Australia's Biggest Morning Tea, Relay For Life, or you can host a fundraiser of your own and Do it For Cancer, any time you like. Get involved with your colleagues and friends to raise funds for vital support services, education and research, prevention and early detection campaigns.

Volunteer with us

People from all walks of life volunteer with Cancer Council ACT, bringing with them a wealth of skills, knowledge and experience. There are so many ways to volunteer your time and energy for Cancer Council ACT and we are always looking for dedicated volunteers to help us.

Leave a Lasting Legacy

Leaving a gift in your Will to Cancer Council ACT is a beautiful legacy. Every gift, regardless of its value, is appreciated. Gifts in Wills provide essential funds for support services, education and research in our local community.

Donate in memory of a loved one

When someone close to you passes away, a gift to Cancer Council ACT can be a meaningful tribute to your loved one. It is also a way to express hope for a Cancer Free Future.

Workplace Giving

Making a gift from your pre-tax pay is one of the simplest, most tax and cost-effective ways to donate. Employers can also show staff that they support the choices they make by matching funds donated by their employees. By setting up an automated pre-tax payroll deduction from your salary you stand with us as a committed supporter of a Cancer Free Future.

Buy Cancer Council sun protection products

A full range of sun protection merchandise is available through the Cancer Council Shop online at www.cancercouncilshop.org.au. Every purchase helps you prevent cancer and contributes financially to our goαls.

Our donor relation team would appreciate a chat with you about how we can turn these ideas into action. Call us now on **02 6257 9999** or email events@actcancer.org.



Cancer Council ACT 1/173 Strickland Crescent Deakin ACT 2600 Tel: 02 6257 9999 Fax: 02 6257 5055 reception@actcancer.org www.actcancer.org ABN: 33 113 296 601